One third of the depressed patients do not respond adequately to conventional treatment. This seems to be associated with increased production of proinflammatory cytokines such as TNF-a and IL-1, as well as dysregulation of cortisol levels. This project aims to investigate Investigate the effectiveness of TaKeTiNa music therapy in the treatment of patients with clinical diagnosis of moderate to severe depression Investigate the physiological and pathophysiological effects of TaKeTiNa using novel blood based biomarkers of depression, especially LDL cholesterol as well as on immune system function in order to establish immune system based biomarkers for better diagnosis and therapy monitoring of major depressive disorder.
The goal of this clinical study's to analyse the impact of TaKeTiNa music therapy in depressed patients.~The main question[s] it aims to answer are:~. Can TaKeTiNa result in a significant pre-to-post intervention decline of depression severity 2. Can TaKeTiNa result in a significantly lower post-intervention depression severity in the T1/T2 group than in the W1/W2 group.~Participants will~be randomly assigned to the two groups, intervention vs. waitlist~receive either an eight week TaKeTiNa music therapy or waitlist~be analysed using questionaires, blood taking, cortisol saliva analysis, measured heart rate variability~Researchers will compare a waitlist to see if TakeTiNa is superior to waitlist